https://m2.mtmt.hu/ hun 2026-06-24 10:23 JournalArticle 31997628 VALIDATED true Nanomedicine Research and Education Center, Institute of Translational Medicine, Semmelweis University, Budapest, Hungary SeroScience LCC, Budapest, Hungary TECOdevelopment GmbH, Rheinbach, Germany MTA-ELTE Complement Research Group, Eötvös Loránd Research Network (ELKH), Department of Immunology, ELTE Eötvös Loránd University, Budapest, Hungary Second Department of Bioinformatics and Pediatrics, Semmelweis University, Budapest, Hungary Lendület Cancer Biomarker Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary Nanotechnology Characterization Lab, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, United States Department of Immunology, ELTE Eötvös Loránd University, Budapest, Hungary Department of Nanobiotechnology and Regenerative Medicine, Faculty of Health, Miskolc University, Miskolc, Hungary Export Date: 25 April 2025; Cited By: 15; Correspondence Address: J. Szebeni; Nanomedicine Research and Education Center, Institute of Translational Medicine, Semmelweis University, Budapest, Hungary; email: szebeni.janos@med.semmelweis-univ.hu 0 false 2026-05-20T19:19:15.841+0000 2026-01-29T15:09:01.389+0000 2021-05-04T08:12:05.536+0000 true 10069606 Pintér Ibolya Katalin /api/admin/10069606 Admin Pintér Ibolya Katalin (SE_AOK_TranszlációsMedInt_Admin5_PI, admin) true 2026-01-29T16:07:43.412+0000 2024-12-06T17:58:09.879+0000 true 10039043 Milánkovics Róbert /api/admin/10039043 Admin Milánkovics Róbert (PTE ÁOK admin 4) true 10039043 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Kozma, Gergely Tibor true true /api/journal/10023324 REVIEWED FRONTIERS IN IMMUNOLOGY 1664-3224 1664-3224 true false 10023324 false 10023324 true 1664-3224 1664-3224 Journal FOREIGN 12 642860 642860 13 2021 Funding 2009274 /api/funding/2009274 (825825) false true Funding 2009275 /api/funding/2009275 European Union Horizon 2020 projects(952520) false true Funding 2009276 /api/funding/2009276 (2nd Department of Pediatry, Semmelweis University) false true Funding 2009277 /api/funding/2009277 (0106307) Támogató: MTA false true Funding 2009278 /api/funding/2009278 (D11206) false true Funding 2009279 /api/funding/2009279 (NKFIH-1157/8/2019) false true true true 2021 true true true false true false GOLD 2026-05-20 true https://doi.org/10.3389/fimmu.2021.642860 16 0 16 10 5 16 16 13 15 16 16 10 10 10 6 0 16 10 16 10 0 9 9 Folyóiratcikk Journal Article 24 15 Könyvrészlet Chapter in Book 25 1 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2021 0 1 0 1 0 2022 0 3 3 3 3 2023 0 6 3 6 3 2024 0 5 3 5 3 2025 0 1 1 1 1 Q1 false 10024742,10035041 false false false 2021-05-24T07:55:49.278+0000 Elméleti Egészségtudományok Intézete (ME / ETK); II. Sz. Gyermekgyógyászati Klinika (SE / AOK / K); Immunológiai Tanszék (ELTE / TTK / Bio_I); MTA-ELTE Komplement Kutatócsoport (ELTE / TTK / Bio_I / Imm_Tsz); Nanomedicina Kutató és Oktató Központ (SE / AOK / I / KKI); Onkológiai Biomarker Kutatócsoport (Lendület) (HRN TTK / MÉI); Transzlációs Medicina Intézet (SE / AOK / I) 8 59 7 11 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 96179915 /api/authorship/96179915 Kozma, Gergely Tibor [Kozma, Gergely Tibor (Immunológia, Mole...), szerző] Nanomedicina Kutató és Oktató Központ (SE / AOK / I / KKI); Transzlációs Medicina Intézet (SE / AOK / I) 1 0.091 true false false Author 10024742 /api/author/10024742 Kozma Gergely Tibor (Immunológia, Molekuláris biológia) Kozma Gergely Tibor true 10024742 true Kozma Gergely Tibor true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96179916 /api/authorship/96179916 Mészáros, Tamás [Mészáros, Tamás (nanomedicina), szerző] Nanomedicina Kutató és Oktató Központ (SE / AOK / I / KKI) 2 0.091 false false false Author 10064003 /api/author/10064003 Mészáros Tamás (nanomedicina) Mészáros Tamás true 10064003 true Mészáros Tamás true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96179917 /api/authorship/96179917 Bakos, Tamás [Bakos, Tamás (Immunológia), szerző] Nanomedicina Kutató és Oktató Központ (SE / AOK / I / KKI) 3 0.091 false false false Author 10070223 /api/author/10070223 Bakos Tamás (Immunológia) Bakos Tamás true true Bakos Tamás true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96179918 /api/authorship/96179918 Hennies, Mark 4 0.09090909 false false false Hennies Mark true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96179919 /api/authorship/96179919 Bencze, Dániel [Bencze, Dániel (Immunológia), szerző] Immunológiai Tanszék (ELTE / TTK / Bio_I) 5 0.09090909 false false false Author 10075321 /api/author/10075321 Bencze Dániel (Immunológia) Bencze Dániel true true Bencze Dániel true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96179920 /api/authorship/96179920 Uzonyi, Barbara [Uzonyi, Barbara (Immunológia), szerző] MTA-ELTE Komplement Kutatócsoport (ELTE / TTK / Bio_I / Imm_Tsz) 6 0.091 false false false Author 10035041 /api/author/10035041 Uzonyi Barbara (Immunológia) Uzonyi Barbara true 10035041 true Uzonyi Barbara true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96179921 /api/authorship/96179921 Győrffy, Balázs [Győrffy, Balázs (Onkológia), szerző] II. Sz. Gyermekgyógyászati Klinika (SE / AOK / K); Onkológiai Biomarker Kutatócsoport (Lendület) (HRN TTK / MÉI) 7 0.091 false false false Author 10000109 /api/author/10000109 Győrffy Balázs (Onkológia) Győrffy Balázs true 10000109 true Győrffy Balázs true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96179922 /api/authorship/96179922 Cedrone, Edward 8 0.09090909 false false false Cedrone Edward true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96179923 /api/authorship/96179923 Dobrovolskaia, Marina A. 9 0.09090909 false false false Dobrovolskaia Marina A. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96179924 /api/authorship/96179924 Józsi, Mihály [Józsi, Mihály (Immunológia), szerző] Immunológiai Tanszék (ELTE / TTK / Bio_I); MTA-ELTE Komplement Kutatócsoport (ELTE / TTK / Bio_I / Imm_Tsz) 10 0.09090909 false false false Author 10019323 /api/author/10019323 Józsi Mihály (Immunológia) Józsi Mihály true 10019323 true Józsi Mihály true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96179925 /api/authorship/96179925 Szebeni, János ✉ [Szebeni, János (Klinikai orvostud...), szerző] Nanomedicina Kutató és Oktató Központ (SE / AOK / I / KKI); Elméleti Egészségtudományok Intézete (ME / ETK) 11 0.091 false true true Author 10003266 /api/author/10003266 Szebeni János (Klinikai orvostudomány, immunológia, nanomedicina) Szebeni János true 10003266 true Szebeni János true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 18739325 /api/publicationidentifier/18739325 DOI: 10.3389/fimmu.2021.642860 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.3389/fimmu.2021.642860 https://doi.org/10.3389/fimmu.2021.642860 false true PublicationIdentifier 18832089 /api/publicationidentifier/18832089 WoS: 000649285000001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 000649285000001 https://www.webofscience.com/wos/woscc/full-record/000649285000001 false true PublicationIdentifier 26897034 /api/publicationidentifier/26897034 EDIT: 110763 SwordSource 92 /api/publicationsource/92 EDIT PublicationSourceType 10007 /api/publicationsourcetype/10007 Repozitórium true true true EDIT EDIT https://edit.elte.hu/xmlui/handle/10831/@@@ true true 92 true GREEN true 110763 https://edit.elte.hu/xmlui/handle/10831/110763 false true PublicationIdentifier 18872894 /api/publicationidentifier/18872894 Scopus: 85105941183 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85105941183 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85105941183 false true PublicationIdentifier 18872895 /api/publicationidentifier/18872895 PubMed: 33995361 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 33995361 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33995361&dopt=Abstract false true SjrRating 11219532 /api/sjrrating/11219532 sjr:Q1 (2021) Scopus - Immunology FRONTIERS IN IMMUNOLOGY 1664-3224 31 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2403 /api/classificationexternal/2403 Scopus - Immunology true 2403 true Q1 DIRECT true true Reference 20226949 /api/reference/20226949 1. Lee 2014: Current concepts in the diagnosis and management of cytokine release syndrome, Blood., 124, p. 188, DOI: 10.1182/blood-2014-05-552729 1 10.1182/blood-2014-05-552729 false true Reference 20226950 /api/reference/20226950 2. Kroschinsky 2017: New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management, Crit Care., 21, p. 89, DOI: 10.1186/s13054-017-1678-1 2 10.1186/s13054-017-1678-1 false true Reference 20226951 /api/reference/20226951 3. Ragab 2020: The COVID-19 Cytokine Storm; What We Know So Far, Front Immunol., 11, p. 1446, DOI: 10.3389/fimmu.2020.01446 3 10.3389/fimmu.2020.01446 false true Reference 20226952 /api/reference/20226952 4. Buszko 2020: The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge, Nat Immunol., 21, p. 1146, DOI: 10.1038/s41590-020-0779-1 4 10.1038/s41590-020-0779-1 false true Reference 20226953 /api/reference/20226953 5. Del Valle 2020: An inflammatory cytokine signature predicts COVID-19 severity and survival, Nat Med., 26, p. 1636, DOI: 10.1038/s41591-020-1051-9 5 10.1038/s41591-020-1051-9 false true Reference 20226954 /api/reference/20226954 6. Dobrovolskaia 2015: Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy, J Control Release., 220, p. 571, DOI: 10.1016/j.jconrel.2015.08.056 6 10.1016/j.jconrel.2015.08.056 false true Reference 20226955 /api/reference/20226955 7. Cedrone 2017: Anticoagulants influence the performance of in vitro assays intended for characterization of nanotechnology-based formulations, Molecules., 23, p. 12, DOI: 10.3390/molecules23010012 7 10.3390/molecules23010012 false true Reference 20226956 /api/reference/20226956 8. Potter 2018: Analysis of pro-inflammatory cytokine and type II interferon induction by nanoparticles, Methods Mol Biol., 1682, p. 173, DOI: 10.1007/978-1-4939-7352-1_15 8 10.1007/978-1-4939-7352-1_15 false true Reference 20226957 /api/reference/20226957 9. Bosmann 2012: Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis, Adv Exp Med Biol., 946, p. 147, DOI: 10.1007/978-1-4614-0106-3_9 9 10.1007/978-1-4614-0106-3_9 false true Reference 20226958 /api/reference/20226958 10. Bobkov 2017: Recombinant C1 esterase inhibitor reduces cytokine storm in an ex vivo whole blood model, J Interferon Cytokine Res., 37, p. 325, DOI: 10.1089/jir.2016.0114 10 10.1089/jir.2016.0114 false true Reference 20226959 /api/reference/20226959 11. Yoshitatsu 1999: Expression of PI-anchored mini-factor H on porcine endothelial cells: potential use in xenotransplantation, Transplant Proc., 31, p. 2812, DOI: 10.1016/S0041-1345(99)00577-1 11 10.1016/S0041-1345(99)00577-1 false true Reference 20226960 /api/reference/20226960 12. Schmidt 2013: Rational engineering of a minimized immune inhibitor with unique triple-targeting properties, J Immunol., 190, p. 5712, DOI: 10.4049/jimmunol.1203548 12 10.4049/jimmunol.1203548 false true Reference 20226961 /api/reference/20226961 13. Nichols 2015: An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy, Kidney Int., 88, p. 1314, DOI: 10.1038/ki.2015.233 13 10.1038/ki.2015.233 false true Reference 20226962 /api/reference/20226962 14. Yang 2018: An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy, J Am Soc Nephrol., 29, p. 1649, DOI: 10.1681/ASN.2017091006 14 10.1681/ASN.2017091006 false true Reference 20226963 /api/reference/20226963 15. Meszaros 2016: Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in vitro, Nanomedicine., 12, p. 1023, DOI: 10.1016/j.nano.2015.11.019 15 10.1016/j.nano.2015.11.019 false true Reference 20226964 /api/reference/20226964 16. Sun 2020: Emerging Role of IL-10 in Hypertrophic Scars, Front Med., 7, p. 438, DOI: 10.3389/fmed.2020.00438 16 10.3389/fmed.2020.00438 false true Reference 20226965 /api/reference/20226965 17. Wei 2020: IL-10 and IL-22 in Mucosal Immunity: Driving Protection and Pathology, Front Immunol., 11, p. 1315, DOI: 10.3389/fimmu.2020.01315 17 10.3389/fimmu.2020.01315 false true Reference 20226966 /api/reference/20226966 18. Porro 2020: The regulatory role of IL-10 in neurodegenerative diseases, Biomolecules., 10, p. 1017, DOI: 10.3390/biom10071017 18 10.3390/biom10071017 false true Reference 20226967 /api/reference/20226967 19. Fang 2020: Molecular switches for regulating the differentiation of inflammatory and IL-10-producing anti-inflammatory T-helper cells, Cell Mol Life Sci., 77, p. 289, DOI: 10.1007/s00018-019-03277-0 19 10.1007/s00018-019-03277-0 false true Reference 20226968 /api/reference/20226968 20. Hebecker 2013: An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H, J Immunol., 191, p. 912, DOI: 10.4049/jimmunol.1300269 20 10.4049/jimmunol.1300269 false true Reference 20226969 /api/reference/20226969 21. Castiblanco-Valencia 2012: Leptospiral immunoglobulin-like proteins interact with human complement regulators factor H, FHL-1, FHR-1, and C4BP, J Infect Dis., 205, p. 995, DOI: 10.1093/infdis/jir875 21 10.1093/infdis/jir875 false true Reference 20226970 /api/reference/20226970 22. NCL ITA protocolsNCL method for cytokine analysis.2020 22 false true Reference 20226971 /api/reference/20226971 23. Sau 2003: The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism, J Biol Chem., 278, p. 37561, DOI: 10.1074/jbc.M306137200 23 10.1074/jbc.M306137200 false true Reference 20226972 /api/reference/20226972 24. Del Prete 1993: Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production, J Immunol., 150, p. 353 24 false true Reference 20226973 /api/reference/20226973 25. Dobrovolskaia 2002: Toll receptors, CD14, and macrophage activation and deactivation by LPS, Microbes Infect., 4, p. 903, DOI: 10.1016/S1286-4579(02)01613-1 25 10.1016/S1286-4579(02)01613-1 false true Reference 20226974 /api/reference/20226974 26. Arnaldez 2020: The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response, J Immunother Cancer., 8, p. e000930, DOI: 10.1136/jitc-2020-000930 26 10.1136/jitc-2020-000930 false true Reference 20226975 /api/reference/20226975 27. Rodriguez Perez 2020: Cellular immunotherapy: a clinical state-of-the-art of a new paradigm for cancer treatment, Clin Transl Oncol., 22, p. 1923, DOI: 10.1007/s12094-020-02344-4 27 10.1007/s12094-020-02344-4 false true Reference 20226976 /api/reference/20226976 28. Hoiland 2020: Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome, Br J Haematol., 190, p. e150, DOI: 10.1111/bjh.16961 28 10.1111/bjh.16961 false true Reference 20226977 /api/reference/20226977 29. Dobrovolskaia 2020: Use of human peripheral blood mononuclear cells to define immunological properties of nucleic acid nanoparticles, Nat Protoc., 15, p. 3678, DOI: 10.1038/s41596-020-0393-6 29 10.1038/s41596-020-0393-6 false true Reference 20226978 /api/reference/20226978 30. Sato 2003: Direct binding of Toll-like receptor 2 to zymosan, and zymosan-induced NF-kappa B activation and TNF-alpha secretion are down-regulated by lung collectin surfactant protein A, J Immunol., 171, p. 417, DOI: 10.4049/jimmunol.171.1.417 30 10.4049/jimmunol.171.1.417 false true Reference 20226979 /api/reference/20226979 31. Zhang 2007: Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo, Blood, 110, p. 228, DOI: 10.1182/blood-2006-12-063636 31 10.1182/blood-2006-12-063636 false true Reference 20226980 /api/reference/20226980 32. Brown 2006: Dectin-1: a signalling non-TLR pattern-recognition receptor, Nat Rev Immunol., 6, p. 33, DOI: 10.1038/nri1745 32 10.1038/nri1745 false true Reference 20226981 /api/reference/20226981 33. Goodridge 2007: Dectin-1 stimulation by Candida albicans yeast or zymosan triggers NFAT activation in macrophages and dendritic cells, J Immunol., 178, p. 3107, DOI: 10.4049/jimmunol.178.5.3107 33 10.4049/jimmunol.178.5.3107 false true Reference 20226982 /api/reference/20226982 34. Soltis 1979: Studies on the nature of heat-labile anti-complementary activity in normal human serum, Clin Exp Immunol., 37, p. 310, DOI: 10.1016/S0022-1759(98)00214-2 34 10.1016/S0022-1759(98)00214-2 false true Reference 20226983 /api/reference/20226983 35. Leshem 1999: Heat inactivation of fetal calf serum is not required for in vitro measurement of lymphocyte functions, J Immunol Methods., 223, p. 249, DOI: 10.1016/S0022-1759(98)00214-2 35 10.1016/S0022-1759(98)00214-2 false true Reference 20226984 /api/reference/20226984 36. Lesniak 2010: Serum heat inactivation affects protein corona composition and nanoparticle uptake, Biomaterials., 31, p. 9511, DOI: 10.1016/j.biomaterials.2010.09.049 36 10.1016/j.biomaterials.2010.09.049 false true Reference 20226985 /api/reference/20226985 37. Whaley 1976: Modulation of the alternative complement pathways by beta 1 H globulin, J Exp Med., 144, p. 1147, DOI: 10.1084/jem.144.5.1147 37 10.1084/jem.144.5.1147 false true Reference 20226986 /api/reference/20226986 38. Szebeni 1995: Complement activation by liposome-encapsulated hemoglobin in vitro: the role of endotoxin contamination, Artif Cells Blood Substit Biotechnol, 23, p. 355, DOI: 10.3109/10731199509117952 38 10.3109/10731199509117952 false true Reference 20226987 /api/reference/20226987 39. Gorski 1979: C4a: the third anaphylatoxin of the human complement system, Proc Natl Acad Sci USA., 76, p. 5299, DOI: 10.1073/pnas.76.10.5299 39 10.1073/pnas.76.10.5299 false true Reference 20226988 /api/reference/20226988 40. Pryzdial 1987: Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact, J Biol Chem., 262, p. 1519, DOI: 10.1016/S0021-9258(19)75665-8 40 10.1016/S0021-9258(19)75665-8 false true Reference 20226989 /api/reference/20226989 41. Kaiser 1995: Significant reduction of factor D and immunosuppressive complement fragment Ba by hemofiltration, Blood Purif., 13, p. 314, DOI: 10.1159/000170215 41 10.1159/000170215 false true Reference 20226990 /api/reference/20226990 42. Ambrus 1990: The Ba fragment of complement factor B inhibits human B lymphocyte proliferation, J Immunol., 144, p. 1549 42 false true Reference 20226991 /api/reference/20226991 43. Nataf 1999: Human T cells express the C5a receptor and are chemoattracted to C5a, J Immunol., 162, p. 4018 43 false true Reference 20226992 /api/reference/20226992 44. Buscema 2017: Immunological response to nitroglycerin-loaded shear-responsive liposomes in vitro and in vivo, J Control Release, 264, p. 14, DOI: 10.1016/j.jconrel.2017.08.010 44 10.1016/j.jconrel.2017.08.010 false true Reference 20226993 /api/reference/20226993 45. Rollwagen 1996: Multiple responses to administration of liposome-encapsulated hemoglobin (LEH): Effects on hematopoiesis and serum IL-6 levels, Exp Hematol., 24, p. 429 45 false true Reference 20226994 /api/reference/20226994 46. Szebeni 1994: Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation, Biochem Biophys Res Comm., 205, p. 255, DOI: 10.1006/bbrc.1994.2658 46 10.1006/bbrc.1994.2658 false true Reference 20226995 /api/reference/20226995 47. Sallenave 2020: Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: key therapeutic targets?, Front Immunol., 11, p. 1229, DOI: 10.3389/fimmu.2020.01229 47 10.3389/fimmu.2020.01229 false true Reference 20226996 /api/reference/20226996 48. Allegra 2020: Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies, Ann Hematol., 99, p. 1953, DOI: 10.1007/s00277-020-04182-4 48 10.1007/s00277-020-04182-4 false true Reference 20226997 /api/reference/20226997 49. Azkur 2020: Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19, Allergy., 75, p. 1564, DOI: 10.1111/all.14364 49 10.1111/all.14364 false true Reference 20226998 /api/reference/20226998 50. Szebeni 2012: A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines, Adv Drug Deliv Rev., 64, p. 1706, DOI: 10.1016/j.addr.2012.07.005 50 10.1016/j.addr.2012.07.005 false true Reference 20226999 /api/reference/20226999 51. Szebeni 2018: Mechanism of nanoparticle-induced hypersensitivity in pigs: complement or not complement?, Drug Discov Today., 23, p. 487, DOI: 10.1016/j.drudis.2018.01.025 51 10.1016/j.drudis.2018.01.025 false true Reference 20227000 /api/reference/20227000 52. Carvelli 2020: Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis, Nature., 588, p. 146, DOI: 10.1038/s41586-020-2600-6 52 10.1038/s41586-020-2600-6 false true Reference 20227001 /api/reference/20227001 53. Noris 2020: The case of complement activation in COVID-19 multiorgan impact, Kidney Int., 98, p. 314, DOI: 10.1016/j.kint.2020.05.013 53 10.1016/j.kint.2020.05.013 false true Reference 20227002 /api/reference/20227002 54. Diurno 2020: Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience, Eur Rev Med Pharmacol Sci., 24, p. 4040, DOI: 10.26355/eurrev_202004_20875 54 10.26355/eurrev_202004_20875 false true Reference 20227003 /api/reference/20227003 55. Laurence 2020: Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19, Clin Immunol, 219, p. 108555, DOI: 10.1016/j.clim.2020.108555 55 10.1016/j.clim.2020.108555 false true Reference 20227004 /api/reference/20227004 56. Conway 2020: Is the COVID-19 thrombotic catastrophe complement-connected?, J Thromb Haemost., 1, p. 1, DOI: 10.1111/jth.15050 56 10.1111/jth.15050 false true Reference 20227005 /api/reference/20227005 57. Gupta 2020: Increased Complement Receptor-3 levels in monocytes and granulocytes distinguish COVID-19 patients with pneumonia from those with mild symptoms, Int J Infect Dis., 99, p. 381, DOI: 10.1016/j.ijid.2020.08.004 57 10.1016/j.ijid.2020.08.004 false true Reference 20227006 /api/reference/20227006 58. Maglakelidze 2020: A review: Does complement or the contact system have a role in protection or pathogenesis of COVID-19?, Pulm Ther., 6, p. 169, DOI: 10.1007/s41030-020-00118-5 58 10.1007/s41030-020-00118-5 false true Reference 20227007 /api/reference/20227007 59. Mastellos 2020: Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy, Clin Immunol., 220, p. 108598, DOI: 10.1016/j.clim.2020.108598 59 10.1016/j.clim.2020.108598 false true Reference 20227008 /api/reference/20227008 60. Mastaglio 2020: The first case of COVID-19 treated with the complement C3 inhibitor AMY-101, Clin Immunol., 215, p. 108450, DOI: 10.1016/j.clim.2020.108450 60 10.1016/j.clim.2020.108450 false true Reference 20227009 /api/reference/20227009 61. Polycarpou 2020: Rationale for targeting Complement in COVID-19, EMBO Mol Med., 12, p. e202012642, DOI: 10.15252/emmm.202012642 61 10.15252/emmm.202012642 false true Reference 20227010 /api/reference/20227010 62. Ramlall 2020: Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection, Nat Med., 26, p. 1609, DOI: 10.1038/s41591-020-1021-2 62 10.1038/s41591-020-1021-2 false true Reference 20227011 /api/reference/20227011 63. Skendros 2020: Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis, J Clin Invest., 130, p. 6151, DOI: 10.1101/2020.06.15.20131029 63 10.1101/2020.06.15.20131029 false true Reference 20227012 /api/reference/20227012 64. Holter 2020: Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients, Proc Natl Acad Sci USA., 117, p. 25018, DOI: 10.1073/pnas.2010540117 64 10.1073/pnas.2010540117 false true Reference 20227013 /api/reference/20227013 65. Yu 2020: Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition, Blood., 136, p. 2080, DOI: 10.1182/blood.2020008248 65 10.1182/blood.2020008248 false true Reference 20227014 /api/reference/20227014 66. Abdin 2020: Tackling the cytokine storm in COVID-19, challenges and hopes, Life Sci., 257, p. 118054, DOI: 10.1016/j.lfs.2020.118054 66 10.1016/j.lfs.2020.118054 false true Reference 20227015 /api/reference/20227015 67. Bellgrau 2020: The cytokine storm—an appropriate, over-reactive response to SARS-COV-2 or the wrong immune pathway?, Scand J Immunol., 93, p. e12979, DOI: 10.1111/sji.12979 67 10.1111/sji.12979 false true Reference 20227016 /api/reference/20227016 68. Paniri 2020: Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation, Life Sci., 257, p. 118114, DOI: 10.1016/j.lfs.2020.118114 68 10.1016/j.lfs.2020.118114 false true Reference 20227017 /api/reference/20227017 69. Quirch 2020: Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review, J Med Internet Res., 22, p. e20193, DOI: 10.2196/20193 69 10.2196/20193 false true Reference 20227018 /api/reference/20227018 70. Rojas 2020: Convalescent plasma in Covid-19: Possible mechanisms of action, Autoimmun Rev., 19, p. 102554, DOI: 10.1016/j.autrev.2020.102554 70 10.1016/j.autrev.2020.102554 false true Reference 20227019 /api/reference/20227019 71. Zhao 2014: Complement anaphylatoxin C4a inhibits C5a-induced neointima formation following arterial injury, Mol Med Rep., 10, p. 45, DOI: 10.3892/mmr.2014.2176 71 10.3892/mmr.2014.2176 false true Reference 20227020 /api/reference/20227020 72. Li 2017: A teleost complement factor Ba possesses antimicrobial activity and inhibits bacterial infection in fish, Dev Comp Immunol., 71, p. 49, DOI: 10.1016/j.dci.2017.01.021 72 10.1016/j.dci.2017.01.021 false true /api/publication/31997628 Kozma Gergely Tibor et al. Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm. (2021) FRONTIERS IN IMMUNOLOGY 1664-3224 1664-3224 12<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10024742"><a href="/gui2/?type=authors&mode=browse&sel=10024742" target="_blank">Kozma Gergely Tibor (<span class="authorship-author-name">Kozma Gergely Tibor</span> <span class="authorAux-mtmt"> Immunológia, Molekuláris biológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Transzlációs Medicina Intézet">TMI</span>/Nanomedicina Kutató és Oktató Központ; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Transzlációs Medicina Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10064003"><a href="/gui2/?type=authors&mode=browse&sel=10064003" target="_blank">Mészáros Tamás (<span class="authorship-author-name">Mészáros Tamás</span> <span class="authorAux-mtmt"> nanomedicina</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Transzlációs Medicina Intézet">TMI</span>/Nanomedicina Kutató és Oktató Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10070223"><a href="/gui2/?type=authors&mode=browse&sel=10070223" target="_blank">Bakos Tamás (<span class="authorship-author-name">Bakos Tamás</span> <span class="authorAux-mtmt"> Immunológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Transzlációs Medicina Intézet">TMI</span>/Nanomedicina Kutató és Oktató Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Hennies Mark </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10075321"><a href="/gui2/?type=authors&mode=browse&sel=10075321" target="_blank">Bencze Dániel (<span class="authorship-author-name">Bencze Dániel</span> <span class="authorAux-mtmt"> Immunológia</span>) </a> </span> <span class="author-affil"><span title="Eötvös Loránd Tudományegyetem">ELTE</span>/<span title="Természettudományi Kar">TTK</span>/<span title="Biológiai Intézet">Bio_I</span>/Immunológiai Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10035041"><a href="/gui2/?type=authors&mode=browse&sel=10035041" target="_blank">Uzonyi Barbara (<span class="authorship-author-name">Uzonyi Barbara</span> <span class="authorAux-mtmt"> Immunológia</span>) </a> </span> <span class="author-affil"><span title="Eötvös Loránd Tudományegyetem">ELTE</span>/<span title="Természettudományi Kar">TTK</span>/<span title="Biológiai Intézet">Bio_I</span>/<span title="Immunológiai Tanszék">Imm_Tsz</span>/MTA-ELTE Komplement Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10000109"><a href="/gui2/?type=authors&mode=browse&sel=10000109" target="_blank">Győrffy Balázs (<span class="authorship-author-name">Győrffy Balázs</span> <span class="authorAux-mtmt"> Onkológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/II. Sz. Gyermekgyógyászati Klinika; <span title="Természettudományi Kutatóközpont">TTK</span>/<span title="Enzimológiai Intézet">EI</span>/Onkológiai Biomarker Kutatócsoport (Lendület)</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Cedrone Edward </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Dobrovolskaia Marina A. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10019323"><a href="/gui2/?type=authors&mode=browse&sel=10019323" target="_blank">Józsi Mihály (<span class="authorship-author-name">Józsi Mihály</span> <span class="authorAux-mtmt"> Immunológia</span>) </a> </span> <span class="author-affil"><span title="Eötvös Loránd Tudományegyetem">ELTE</span>/<span title="Természettudományi Kar">TTK</span>/<span title="Biológiai Intézet">Bio_I</span>/Immunológiai Tanszék; <span title="Eötvös Loránd Tudományegyetem">ELTE</span>/<span title="Természettudományi Kar">TTK</span>/<span title="Biológiai Intézet">Bio_I</span>/<span title="Immunológiai Tanszék">Imm_Tsz</span>/MTA-ELTE Komplement Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10003266"><a href="/gui2/?type=authors&mode=browse&sel=10003266" target="_blank">Szebeni János ✉ (<span class="authorship-author-name">Szebeni János</span> <span class="authorAux-mtmt"> Klinikai orvostudomány, immunológia, nanomedicina</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Transzlációs Medicina Intézet">TMI</span>/Nanomedicina Kutató és Oktató Központ; <span title="Miskolci Egyetem">ME</span>/<span title="Egészségtudományi Kar ">ETK</span>/Elméleti Egészségtudományok Intézete</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;31997628" target="_blank">Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm</a></div> <div> <span class="journal-title">FRONTIERS IN IMMUNOLOGY</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/1664-3224">1664-3224</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1664-3224">1664-3224</a>)</span>: <span class="journal-volume">12</span> <span class="page"> Paper 642860. 13 p. </span> <span class="year">(2021)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.3389/fimmu.2021.642860" target="_blank" href="https://doi.org/10.3389/fimmu.2021.642860"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="000649285000001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/000649285000001"> WoS </a> </span> <span class="id identifier oa_GREEN" title=" Green "> <a style="color:black" title="110763" target="_blank" href="https://edit.elte.hu/xmlui/handle/10831/110763"> EDIT </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85105941183" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85105941183"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="33995361" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33995361&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Immunology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Immunology and Allergy&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 16</span> | Független: 10 | Függő: 6 | Nem jelölt: 0 | WoS jelölt: 13 | Scopus jelölt:&nbsp;15 | WoS/Scopus jelölt:&nbsp;16 | DOI jelölt:&nbsp;16 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;31997628&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 9 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 31997628</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (825825), European Union Horizon 2020 projects(952520), (2nd Department of Pediatry, Semmelweis University), (0106307) Támogató: MTA, (D11206), (NKFIH-1157/8/2019) </div> <div class="lastModified">Utolsó módosítás: 2026.01.29. 16:09 Szabó Regina (ELTE TTK admin 5) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Nanomedicine Research and Education Center, Institute of Translational Medicine, Semmelweis University, Budapest, Hungary SeroScience LCC, Budapest, Hungary TECOdevelopment GmbH, Rheinbach, Germany MTA-ELTE Complement Research Group, Eötvös Loránd Research Network (ELKH), Department of Immunology, ELTE Eötvös Loránd Univers...</pre> </div></div>